Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

In terms of specificity (meaning the ability to correctly identify people without cancer), the Cologuard test has a ...

The approval was based on data from the BLUE-C trial (ClinicalTrials.gov Identifier: NCT04144738), which assessed the sensitivity and specificity of the Cologuard Plus test vs a commercially ...

Among the subset of nearly 19,000 average-risk participants, the Cologuard Plus test demonstrated 95% overall cancer sensitivity and 43% sensitivity for advanced precancerous lesions at 94% ...

It's at least as good. The two key measures of the accuracy of a cancer test are sensitivity (true positives) and specificity (true negatives). Cologuard Plus has an overall sensitivity of 93.9% ...

Moreover, the current generation of Cologuard technology has specificity below 90% (87% in its Deep-C trial) and also low sensitivity for potentially precancerous adenomas (42% in Deep-C).

Because of their low sensitivity to adenomas, Shield and Cologuard both miss important opportunities to prevent cancer altogether. “A colonoscopy is both a diagnostic test and a therapeutic ...

2. In a trial of 19,000 patients, ]Cologuard Plus test demonstrated 95% overall cancer sensitivity and 43% sensitivity for advanced precancerous lesions at 94% specificity. 3. Cologuard Plus ...

The subgroup sensitivity by Cologuard Plus outperformed FIT’s, which showed a 65%, 47% and 23% sensitivity in detecting Stage I-III CRC, high-grade dysplasia and advanced precancerous lesions ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Among the subset of nearly 19,000 average-risk participants, the Cologuard Plus test demonstrated 95% overall cancer sensitivity and 43% sensitivity for advanced precancerous lesions at 94% ...